Skip to main content
Premium Trial:

Request an Annual Quote

Cellectis Bioresearch, Syngene Partner on Cell Line Development

NEW YORK (GenomeWeb News) – Cellectis bioresearch and Indian contract research organization Syngene International said today they will co-develop novel genetically customized cell lines.

The collaboration between the two companies will leverage Paris-based Cellectis bioresearch's genome customization technology and Syngene's biology platform and capabilities to develop recombinant and knock-out cell lines for oncology and ADME-Tox-based drug discovery research.

Financial and other terms of the deal were not disclosed.

"This new partnership with Syngene International will enable us to mobilize each organizations' expertise and know-how and create synergies that will deliver hundreds of engineered cell lines for drug discovery and functional genomics," Cellectis bioresearch CEO Marc Le Bozec, said in a statement.

Cellectis bioresearch is a subsidiary of Cellectis.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.